Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pantoprazole for Reversibility of Esophageal Metaplasia
NCT00161200Phase 3Terminated
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Dec 2002
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pantoprazole in Barrett's esophagus (2 arms), sponsored by University of Medicine and Dentistry of New Jersey. Primary endpoint: Reversibility of Columnar Metaplasia (mAb Das-1 positive to negative) at 6 months. Started Dec 2002; status: terminated.
02
Drugs
pantoprazole
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT00161200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161200.